{"id":"W4408978899","doi":"10.1016/s1556-0864(25)00213-8","title":"18P: Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein–overexpressing nonsquamous EGFR wildtype advanced NSCLC: Updated analysis of the LUMINOSITY trial","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"Chugai Pharmaceutical; Daiichi Sankyo Europe; Gilead Sciences; LEO Pharma; Aptitude Health; Astellas Pharma; Eisai; Sanofi; Apollomics; Ribon Therapeutics; Ipsen; International Association for the Study of Lung Cancer; BeiGene; Les Laboratories Pierre Fabre; Helsinn; Puma Biotechnology; Regeneron Pharmaceuticals; EMD Serono; Mersana Therapeutics; Amgen; Helsinn Therapeutics; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Oncology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001452504,0.0006619889,0.001693619,0.0002945401,0.0001704074,0.00104247,0.0005138129,0.0005795172,0.001836329],"category_scores_gemma":[0.001114632,0.0002836786,0.001512887,0.0004756568,0.000460214,0.001227244,0.0003584812,0.002221678,0.0004138046],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001019314,"about_ca_system_score_gemma":0.0006899668,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008926896,"about_ca_topic_score_gemma":0.004743988,"domain_scores_codex":[0.9996029,0.0001491951,0.00002833285,0.0000764588,0.00006884368,0.00007425328],"domain_scores_gemma":[0.9995595,0.000131535,0.0001393364,0.00003211382,0.00004212327,0.00009534859],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4216414,0.002397924,0.03308036,0.003535244,0.01441905,0.0003483685,0.0002670895,0.004799839,0.01885378,0.001199294,0.01662402,0.4828338],"study_design_scores_gemma":[0.6305245,0.1052455,0.177017,0.001114362,0.02242999,0.001883891,0.0003336571,0.00450207,0.004298396,0.00235549,0.05006322,0.0002318272],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9458321,0.04242541,0.0008772591,0.001738518,0.0004854865,0.0003894615,0.002879386,0.0001380139,0.005234328],"genre_scores_gemma":[0.9728132,0.01556587,0.001061458,0.001886918,0.0003710708,0.0004010946,0.005075309,0.00004103157,0.002783952],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001836329,"threshold_uncertainty_score":0.007681668,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01124500098707715,"score_gpt":0.376675991562523,"score_spread":0.3654309905754458,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}